Project Grant R21AG096943
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $485K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85281, USA
Similar Awards
- The National Institute on Aging awarded Arizona State University $655,917 under the Aging Research program (CFDA 93.866) on August 15, 2026, to develop and validate deep learning methods that enhance retinal color fundus photography image quality, automate retinal biomarker identification for Alzheimer's disease pathology, and enable scalable, cost-effective preclinical AD risk assessment. The project will create an unsupervised method using optimal transport-guided generative adversarial...
- The National Institute on Aging awarded Arizona State University $431,750 under the Aging Research program (CFDA 93.866) on September 1, 2026, to define the mechanisms underlying the protective effects of the RELN-COLBOS variant in Alzheimer's disease. The funded research leverages stem cell bioengineering, genome editing, and neurodegenerative disease modeling to elucidate the neuroprotective mechanisms of the RELN-COLBOS variant, a rare Reelin variant identified in a PSEN1 mutation carrier...
- The National Institute on Aging awarded a $7.287 million cooperative agreement to Arizona State University on September 1, 2026, under the Aging Research program (CFDA 93.866). The award funds a five-year research initiative running through August 31, 2031, examining heterogeneity in aging using a free-ranging rhesus macaque population on Cayo Santiago Island, Puerto Rico—the world's longest-running primate field station. The research program addresses three integrated questions: quantifying how...
- The National Institute on Aging awarded the University of Arizona $396,241 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal, multi-modal study tracking neuroplasticity changes in preclinical and prodromal Alzheimer's disease stages using transcranial magnetic stimulation (TMS) integrated with blood and MRI biomarkers. The study employs TMS to assess non-invasive, repeatable neurophysiological measures of neuroplasticity and correlates these...
- The National Institute on Aging awarded Arizona State University $1,249,351 on September 1, 2026, under the Aging Research program (CFDA 93.866) to examine day-to-day fluctuations in loneliness and their relationship to biological and functional aging outcomes across multiple timescales. The research will identify patterns of daily loneliness—average daily loneliness, loneliness volatility (day-to-day fluctuations), and loneliness reactivity to daily triggers—and map how these patterns predict...
- The National Institute on Aging awarded Arizona State University $436,228 on June 1, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of glucagon-like peptide-1 receptor agonists on sarcopenia in older adults. The research project will measure muscle mass and the mechanisms regulating muscle mass—including muscle protein synthesis and breakdown—using stable isotope tracer methodologies in older patients before and six months after GLP-1 RA treatment. The study will...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded the University of Arizona $616,013 on September 4, 2026, under the Aging Research program (CFDA 93.866) to conduct a Project Grant testing whether enhancing MET receptor tyrosine kinase signaling can rescue synaptic loss and reverse cognitive decline in an Alzheimer's disease mouse model. The research investigates the central hypothesis that synaptic degeneration in Alzheimer's disease can be mitigated by reactivating MET signaling in the adult brain....
- The National Institute on Aging awarded the Fatty Acid Research Institute $412,500 on September 1, 2026, under the Aging Research program (CFDA 93.866) to establish interaction polygenic risk scores for blood omega-3 fatty acids and genetic variants as predictors of incident all-cause dementia and Alzheimer's disease. The research identifies genetic variants that interact with blood docosahexaenoic acid (DHA) levels as risk factors for Alzheimer's disease and related dementias, with the goal...
- The National Institute on Aging awarded the University of Arizona $611,338 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop selective DYRK1A inhibitors for Alzheimer's disease treatment. The research targets dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a therapeutic intervention modulating tau, amyloid, and neuroinflammatory pathways in Alzheimer's disease. Prior work demonstrated that the DYRK1A inhibitor DYR533 improves behavioral and...